New drug may help those who can't take statins

November 5, 2012 in Cardiology

New drug may help those who can't take statins

Study found it lowered LDL cholesterol as well as high doses of statins.

(HealthDay)—An experimental drug may help patients who can't tolerate statins lower their cholesterol, a new Australian study suggests.

The 12-week, phase 2 clinical trial was conducted at 33 international sites and included adults who suffered when taking statins, a class of -lowering drugs that includes Crestor and Lipitor. They received injections of a placebo or different doses of AMG145, which is a .

Human monoclonal antibodies are naturally occurring that are genetically altered in a laboratory, cloned in large numbers and introduced into the patient to target disease sites.

The patients who received AMG145 had 41 percent to 63 percent reductions in "bad" (LDL) cholesterol and did not experience significant muscle-related side effects, said study leader Dr. David Sullivan, of the Royal Prince Alfred Hospital in Australia, and colleagues.

The reductions in LDL cholesterol seen in these patients were comparable to those that occur in patients taking the highest doses of the most effective statins, the researchers added.

One expert found the results intriguing.

"The most interesting aspect of this study is use of a novel approach using monoclonal antibodies—a subtype of antibodies—in the management of elevated LDL cholesterol," said Dr. Kenneth Ong, acting chief of cardiology at the Brooklyn Hospital Center.

"In this phase 2 study, the results are certainly impressive and warrant further investigation," Ong said. "Of note is the reduction in the number of myalgias (muscle pains) for patients compared to the number of myalgias experienced by people taking statins. If larger trials and longer durations of observation confirm these initial findings, many patients whose are otherwise untreated or under-treated could benefit."

Another expert agreed.

"For those patients with elevated LDL who are intolerant to statins, this provides a viable option," said Dr. Suzanne Steinbaum, a preventive cardiologist at Lenox Hill Hospital in New York City. More trials need to be done of this unique treatment, she added.

The study was published online Nov. 5 in the Journal of the American Medical Association, to coincide with a planned presentation at the American Heart Association's annual meeting in Los Angeles.

More information: The American Academy of Family Physicians has more about cholesterol-lowering drugs.

Journal reference: Journal of the American Medical Association search and more info website

Copyright © 2012 HealthDay. All rights reserved.

4 /5 (3 votes)  

Rank 4 /5 (3 votes)
Related Stories
Relevant PhysicsForums posts

More news stories

Second-generation TAVI device—Lotus Valve—shows good performance in REPRISE II

22 May 2013, Paris, France: The Lotus Valve, a second-generation transcatheter aortic valve implantation (TAVI) device, was successfully implanted in all of the first 60 patients in results from REPRISE II reported at EuroPCR ...

Cardiology created 2 hours ago | popularity not rated yet | comments 0

Costs to treat stroke in America may double by 2030

Costs to treat stroke are projected to more than double and the number of people having strokes may increase 20 percent by 2030, according to the American Heart Association/American Stroke Association.

Cardiology created May 22, 2013 | popularity not rated yet | comments 0

New blood-thinner measures may cut medication errors

Blood thinners are the preferred treatment option to prevent heart attacks, blood clots and stroke, but they are not without risk, and not just because of their side effects. These high-risk drugs, known as anticoagulants, ...

Cardiology created May 22, 2013 | popularity not rated yet | comments 0

Registry questions superiority of bivalirudin over heparin

Results from a large observational study reported at EuroPCR 2013 today question whether bivalirudin is superior to heparin in the absence of GPIIb/IIIa blockade, showing similar 30-day mortality in patients with non-ST segment ...

Cardiology created May 22, 2013 | popularity 5 / 5 (1) | comments 0

Study shows low rate of late lumen loss with bioresorbable DESolve device

The DESolve bioresorbable coronary scaffold system achieves good efficacy and safety with low rates of late lumen loss and major coronary adverse events at six months, show first results from the pivotal DESolve Nx trial ...

Cardiology created May 22, 2013 | popularity not rated yet | comments 0


UN reports 22 deaths worldwide from coronavirus

A new coronavirus has now claimed 22 lives worldwide out of 44 lab-confirmed cases, mostly in Saudi Arabia, World Health Organization officials said Thursday.

Motion quotient: IQ predicted by ability to filter motion (w/ video)

A brief visual task can predict IQ, according to a new study. This surprisingly simple exercise measures the brain's unconscious ability to filter out visual movement. The study shows that individuals whose ...

Defective cellular waste removal explains why Gaucher patients often develop Parkinson's disease

Gaucher disease causes debilitating and sometimes fatal neurodegeneration in early childhood. Recent studies have uncovered a link between the mutations responsible for Gaucher disease and an increased risk ...

Protein preps cells to survive stress of cancer growth and chemotherapy

Scientists have uncovered a survival mechanism that occurs in breast cells that have just turned premalignant-cells on the cusp between normalcy and cancers-which may lead to new methods of stopping tumors.

The secret lives, and deaths, of neurons

As the human body fine-tunes its neurological wiring, nerve cells often must fix a faulty connection by amputating an axon—the "business end" of the neuron that sends electrical impulses to tissues or other ...

Regenerating spinal cord fibers may be treatment for stroke-related disabilities

A study by researchers at Henry Ford Hospital found "substantial evidence" that a regenerative process involving damaged nerve fibers in the spinal cord could hold the key to better functional recovery by most stroke victims.